Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 3720931

Next Previous
Drug Profile

BI 3720931

Alternative Names: BI-3720931; Cystic fibrosis gene therapy - Boehringer Ingelheim/Oxford BioMedica/the UK Cystic Fibrosis Gene Therapy Consortium

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The UK Cystic Fibrosis Gene Therapy Consortium
  • Developer Boehringer Ingelheim
  • Class Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cystic fibrosis

Most Recent Events

  • 20 May 2025 Boehringer Ingelheim initiates the phase I/II trial in Cystic fibrosis in United Kingdom (Inhalation) (NCT06962852)
  • 13 May 2025 Boehringer Ingelheim plans the phase I/II Lenticlair™-ON trial in Cystic fibrosis in France, Italy, Netherlands, Spain, United Kingdom (Inhalation) (NCT06962852) (EUCT2023-504909-37-00)
  • 04 Nov 2024 Phase-I/II clinical trials in Cystic fibrosis in Spain, Netherlands, Italy, France, United Kingdom (Inhalation)(EudraCT2023-503281-23-00) (NCT06515002)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top